Enliven Therapeutics, Inc. (ELVN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Boulder, CO, アメリカ. 現CEOは Richard A. Fair.
ELVN を有する IPO日 2020-03-12, 62 名の正社員, に上場 NASDAQ Global Select, 時価総額 $2.63B.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
